Article Versions Notes

Levin MJ, Divino V, Shah D, DeKoven M, Mould-Quevedo J, Pelton SI, Postma MJ. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis. Vaccines. 2021; 9(10):1146. https://doi.org/10.3390/vaccines9101146

Levin, Myron J., Victoria Divino, Drishti Shah, Mitch DeKoven, Joaquin Mould-Quevedo, Stephen I. Pelton, and Maarten J. Postma. 2021. "Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis" Vaccines 9, no. 10: 1146. https://doi.org/10.3390/vaccines9101146

Levin, M. J., Divino, V., Shah, D., DeKoven, M., Mould-Quevedo, J., Pelton, S. I., & Postma, M. J. (2021). Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis. Vaccines, 9(10), 1146. https://doi.org/10.3390/vaccines9101146